Effect of sodium ozagrel on the activity of rat CYP2D6

European Journal of Pharmacology

Volumn 573, Issue 1-3, 2007, Pages 55-59

  Wu, Hong ^a,c   Yu, Weijiang ^a   Huang, Lijun ^a   Wang, Jing ^a   Tang, Xiaobo ^a   Yang, Wei ^a   Liu, Yan ^a   Yu, Huiyan ^a   Zhu, Daling ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Bio pharmaceutical Key Laboratory of Heilongjiang Province   (China)

^c MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

CYP2D6; Dextromethorphan; HPLC; Microsome; Ozagrel

Indexed keywords

CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; OZAGREL; PARACETAMOL; PHENACETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; BLOTTING, WESTERN; BUPRENORPHINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIMETIDINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; KINETICS; MALE; METHACRYLATES; MICROSOMES, LIVER; PHENACETIN; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE-A SYNTHASE;

EID: 34648852389     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.055     Document Type: Article

References (21)

1. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
2. Funck-Brentano C., Boëlle P.Y., Verstuyft C., Bornert C., Becquemont L., and Poirier J.M. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur. J. Clin. Pharmacol. 61 (2005) 821-829
3. Garcia-Martin E., Martinez C., Pizarro R.M., Garcia-Gamito F.J., Gullsten H., Raunio H., and Agundez J.A. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71 (2002) 196-204
4. Gibbson G.G., and Sheet P. Introduction to Drug Metabolism,. 2nd ed (1994), Blackie Academic and Professional, London
5. Guengerich F.P. Human cytochrome P-450 enzymes. Life Sci. 50 (1992) 1471-1478
6. Hu O.Y., Lane H., Chang W., and Hu T. Novel singlepoint plasma or saliva dextromethorphan method for determining CYP2D6 activity. J. Pharmcol. Exp. Ther. 285 (1998) 955-960
7. Knodell R.G., Browne D.G., Gwozdz G.P., Brian W.R., and Guengerich F.P. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101 (1991) 1680-1691
8. Ma J., and Qian B.L. Research advances in human cytochrome P450s and their application in new drug evaluation. Chin. J. New Drugs 11 (2002) 36-42
9. Morita K., Ono T., and Shimakawa H. Effects of ozagrel (OKY-046), a thromboxane synthase inhibitor, on oxidative drug-metabolizing enzymes in mouse hepatic microsomes. J. Pharmacobio-dyn. 11 (1988) 519-525
10. Martinez C., Albet C., Agundez J.A., Herrero E., Carrillo J.A., Marquez M., Benitez J., and Ortiz J.A. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6 and CYP3A by H2-receptor antagonists. Clin. Pharmacol. Ther. 65 (1999) 369-376
11. Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., and Maurel P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6 (1992) 752-758
12. Madeira M., Levine M., Chang T.K.H., Mirfazaelian A., and Bellward G.D. The effect of cimetidine on Dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab. Dispos. 32 (2004) 460-467
13. Monostory K., Hazai E., and Vereczkey L. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem. Biol. Interact. 147 (2004) 331-340
14. Mortimer Ö., Lindstrom B., Laurell H., Bergman U., and Rane A. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br. J. Clin. Pharmacol. 27 (1989) 223-227
15. Navas J.M., Chana A., Herradon B., and Segner H. Induction of CYP1A by the N-imidazole derivative, 1-benzylimidazole. Environ. Toxicol. Chem. 22 (2003) 830-836
16. Navas J.M., Chana A., Herradon B., and Segner H. Induction of cytochrome P4501A (CYP1A) by clotrimazole, a non-planar aromatic compound. Computational studies on structural features of clotrimazole and related imidazole derivatives. Life Sci. 76 (2004) 699-714
17. Powell P.K., Wolf I., and Lasker J.M. Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch. Biochem. Biophys. 335 (1996) 219-226
18. Tachibana S., Tanaka M., Fujimaki Y., Suzuki W., Ookuma T., Ohor i.Y., Hayashi K.I., Iwata H., Okazaki O., and Sudo K.I. Metabolism of the calmodulin antagonist DY-9760e in animals and humans. Xenobiotica 35 (2005) 499-517
19. Yu A.M., Idle J.R., and Gonzalez F.J. Polymorphic cytochrome P4502D6: humanized mouse model and endogenous substrates. Drug Metab Rev. 36 (2004) 243-277
20. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6:overview and update on pharmacology genetics biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 23-37
21. Zhu D.L., Birks E.K., Dawson C.A., Patel M., and John R. Hypoxic pulmonary vasoconstriction is modified by P-450 metabolites. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) 1526-1533